FAQ

Before taking Dipyridamole, inform your doctor about any allergies to the medication and any other medicines you are currently taking. Patients with a history of bleeding disorders, low blood pressure, or those undergoing surgery should discuss using Dipyridamole with their healthcare provider.

The use of Dipyridamole during pregnancy or breastfeeding is advised only under the direct supervision of a doctor. You should discuss the risks with your doctor.

Store Dipyridamole at room temperature away from moisture and heat. Keep it out of reach of children and pets, and dispose of any unused medication through proper take-back programs.

Samsca (tolvaptan) is used to treat hyponatremia (low sodium levels in the blood) associated with conditions like heart failure and certain hormone imbalances. It works by blocking the action of the hormone vasopressin, which helps your body to excrete excess water while retaining sodium.

Samsca should be taken orally, once daily, with or without food. The starting dose is usually 15 mg, which may be increased to 30 mg and up to 60 mg as needed to achieve the desired level of serum sodium. Treatment should not exceed 30 days to minimize the risk of liver damage.

Common side effects include thirst, dry mouth, constipation, weakness, and frequent urination. Serious side effects may include liver problems, which could be fatal. Symptoms of serious side effects include loss of appetite, nausea, vomiting, fever, itching, jaundice, and dark urine.

Samsca treatment should be initiated and re-initiated in a hospital setting to monitor serum sodium levels. It is not recommended for patients with polycystic kidney disease outside of a specific program that includes liver monitoring. Avoid taking Samsca with grapefruit juice or alcoholic beverages as they can increase side effects.

Rapid increase in sodium levels while on Samsca can lead to serious neurological issues, including osmotic demyelination syndrome which can cause symptoms like difficulty speaking, swallowing problems, mood changes, seizures, and in severe cases, coma or death.

Individuals who are unable to urinate or cannot sense when they are thirsty should not use Samsca. Additionally, it should not be used by patients who have severe dehydration or those who need immediate correction of hyponatremia.

The safety of Samsca in pregnant women has not been established. Women who are pregnant or planning to become pregnant should consult their healthcare provider before starting treatment with Samsca.